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Abstract
Low-level laser (light) therapy (LLLT) has been clinically applied around the world for a spectrum of disorders requiring
healing, regeneration and prevention of tissue death. One area that is attracting growing interest in this scope is the use of
transcranial LLLT to treat stroke and traumatic brain injury (TBI). We developed a mouse model of severe TBI induced by
controlled cortical impact and explored the effect of different treatment schedules. Adult male BALB/c mice were divided
into 3 broad groups (a) sham-TBI sham-treatment, (b) real-TBI sham-treatment, and (c) real-TBI active-treatment. Mice
received active-treatment (transcranial LLLT by continuous wave 810 nm laser, 25 mW/cm2, 18 J/cm2, spot diameter 1 cm)
while sham-treatment was immobilization only, delivered either as a single treatment at 4 hours post TBI, as 3 daily
treatments commencing at 4 hours post TBI or as 14 daily treatments. Mice were sacrificed at 0, 4, 7, 14 and 28 days post-TBI
for histology or histomorphometry, and injected with bromodeoxyuridine (BrdU) at days 21–27 to allow identification of
proliferating cells. Mice with severe TBI treated with 1-laser Tx (and to a greater extent 3-laser Tx) had significant
improvements in neurological severity score (NSS), and wire-grip and motion test (WGMT). However 14-laser Tx provided no
benefit over TBI-sham control. Mice receiving 1- and 3-laser Tx had smaller lesion size at 28-days (although the size
increased over 4 weeks in all TBI-groups) and less Fluoro-Jade staining for degenerating neurons (at 14 days) than in TBI
control and 14-laser Tx groups. There were more BrdU-positive cells in the lesion in 1- and 3-laser groups suggesting LLLT
may increase neurogenesis. Transcranial NIR laser may provide benefit in cases of acute TBI provided the optimum
treatment regimen is employed.
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Introduction
Incidences of traumatic brain injury (TBI) in both developed
and developing countries are in rise. Main reasons that can
account for that include growth in population and growing
number of traffic accidents (and other emergencies such as natural
disasters, sports injuries, falls and assaults. Moreover modern
military conflict has led to an additional steep rise in TBI due to
blast injuries as well as direct combat-mediated head injuries [1].
The burden of TBI in USA has been estimated to be 1.5 million
cases each year, with an annual economic cost exceeding $56
billion [2].
The lack of any specifically approved therapy for TBI,
combined with the failure of many clinical trials of pharmaceutical
drugs that have been investigated for TBI, has motivated
researchers to a widen their range in search of novel therapeutic
interventions [3,4]. These intervention avenues can be grouped
into therapies that could potentially affect oxidative stress [5];
inflammation [6]; excitotoxicity [7]; metabolic dysfunction [8];
dysregulated neurochemical pathways [9]; impaired circulation
[10]; brain hypoxia [11]; could increase neuroprotection [12] or
stimulate neurogenesis [2] and could induce brain repair by stem
cells [13]. Some physical intervention methods, such as brain
hypothermia, have shown encouraging results [14].
Low level laser (light) therapy (LLLT), as a potential treatment
avenue, has been clinically applied for a wide range of medical
indications requiring protection from cell and tissue death,
stimulation of healing and repair of injuries, and reduction of
pain, swelling and inflammation [15]. Evidence is suggesting that
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red or near-infra-red light (at wavelengths that can penetrate
tissue) is absorbed by mitochondrial chromophores leading to
increased cellular respiration, more ATP synthesis, modulation of
oxidative stress and nitric oxide production that together lead to
activation of signaling pathways and gene transcription [16]. One
area that is attracting growing interest is the use of transcranial
LLLT to treat stroke [17,18] the success of which has been
demonstrated both in animal models [19] and in clinical trials
[20]. To date, seven published studies on mouse models
[21,22,23,24,25,26,27] have suggested that transcranial LLLT
(810 nm laser could have a beneficial therapeutic effect on TBI as
well. However there are still many questions to be answered, for
instance, what is the best regimen of treatment repetition? One
observation that has been repeatedly made, during the 40 years of
LLLT studies, is that there is a pervasive biphasic dose response
relationship that applies not only in cell culture (in vitro) studies, but
also in pre-clinical (in vivo) animal studies, and even in clinical
reports [28]. It has been found that there is generally an optimum
level of energy density (J/cm2), power density (mW/cm2) and/or
treatment repetition to give the best therapeutic effects and if the
optimum parameter setting is either not reached or else is
substantially exceeded the benefit is reduced [29]. In our current
study we used a controlled cortical impact (CCI) mouse model of
severe TBI, and observed the effects of different treatment
repetitions of 810 nm LLLT on neurobehavioral and vestibulo-
motor functioning; followed the histomorphological analyses, and
histological evidence to track the neuroprotection and neurogen-
esis.
Materials and Methods
2.1 Animals
Ethics statement. All animal procedures were approved by
the Subcommittee on Research Animal Care (IACUC) of the
Massachusetts General Hospital (protocol # 2010N000202) and
met the guidelines of the National Institutes of Health.
Adult male BALB/c mice (6–8 weeks, weight 21 to 25 g;
Charles River Laboratories, Wilmington, MA) were used in the
study. The mice were divided into 9 groups: 3 sham-TBI sham-
treatment groups, 3 real-TBI sham-treatment groups, and 3 real-
TBI active-treatment groups (see later); each group had 16 mice at
the start of the study, allowing for sacrifice of 2mice at time points
and allowing 8mice to remain between 14 and 28 days. The
animals were housed with one mouse per cage and were
maintained on a 12 h light &12 h dark cycle with access to food
and water ad libitem.
2.2 Mouse Model of Controlled Cortical Impact Focal (TBI)
The mice were anesthetized with isoflurane for the surgical
procedure. After the hair on the head was shaved and depilated
(Nair, Carter-Wallace, NY), the top of the skull was adequately
exposed with a 1 cm skin incision made in a central and sagittal
direction. A 5 mm craniotomy was performed over the right
parietotemporal cortex using a trephine attached to an electric
portable drill taking care to avoid damaging the meninges. The
bone flap was removed and mice were subjected to controlled
cortical impact using a pneumatic impact device (Model AMS
201, AmScien Instruments LLC, USA) with a 3 mm flat-tip, high
pressure 150 psi, low pressure 30 psi, rod speed 4.8 m/sec, rising
duration 8.41 ms, and set impact depth of 2 mm with the devise
positioned over the right front-parietal cortex and the tip centered
3 mm anterior to lambda and 2.5 mm right of midline within the
craniotomy; these parameters were selected to yield a trauma
giving a neurological severity score (NSS) of 7–8 measured 1 hour
post-TBI. Immediately after generating the brain trauma the
craniotomy hole was sealed with bone wax, the scalp incision was
closed with sutures. Sham control mice were subjected to all
aspects of the protocol (anesthesia, skin incision, and craniotomy)
except for cortical impact. After recovery from anesthesia, the
mice were returned to their cages with postoperative care and ad
libitem access to food and water. Mice which had NSS scores
greater than 8 or less than 7 were excluded from the study.
2.3 Neurobehavioral Testing
The neurological status of the traumatized mice was evaluated
at different time intervals after CCI according to NSS (Table 1).
The neurological tests are based on the ability of the mice to
perform 10 different tasks [24] that evaluate the motor ability,
balance, and alertness of the mouse. One point is given for failing
to perform each of the tasks; thus, a normal, uninjured mouse
scores 0 and the maximum is 10. The severity of injury is defined
by the initial NSS, evaluated 1 h post-CCI, and is a reliable
predictor of the late outcome. Thus, very severe injury is defined in
mice having an NSS of 9–10; severe injury in mice with an NSS of
7–8; moderate injury with NSS of 5–6, and mild injury in mice
with an NSS of,5. NSS was carried out on days 0, 1, 4, 7, 10, 15,
19, 24, and 28.
Motor function or muscle power was assessed using a wire grip
and motion test (WGMT), which was developed on the basis of the
test of gross vestibulomotor function [30]. The test consisted of
placing the mouse on a thin and horizontal metal wire (45 cm
long) suspended (45 cm above a foam pad) between two poles, and
grading the ability of the mouse to grip, attach and move as
described in Table 2. The wire grip test was performed in triplicate
and an average value calculated for each mouse. WGMT was
carried out on days 0, 1, 4, 7, 10, 15, 19, 24, and 28.
2.4 Laser Treatment
Mice were lightly anesthetized with isoflurane and immobilized
by taping their paws to a plastic plate. Three groups of TBI mice
received active laser treatment with 810 nm continuous wave laser
(DioDent Micro 810, HOYA ConBio, Fremont, CA) using a
fluence of 18 J/cm2 at an irradiance of 25 mW/cm2 taking 12
minutes with a spot size 1 cm diameter positioned centrally on top
of the mouse head and delivered 4 hours post-injury. Group 1
received a single laser Tx, Group 2 received laser treatments on
Table 1. Neurological Severity Score (NSS) for TBI Mice.
Task NSS
Presence of mono- or hemiparesis 1
Inability to walk on a 3-cm-wide beam 1
Inability to walk on a 2-cm-wide beam 1
Inability to walk on a 1-cm-wide beam 1
Inability to balance on a 1-cm-wide beam 1
Inability to balance on a round stick (0.5 cm wide) 1
Failure to exit a 30-cm-diameter circle (for 2 min) 1
Inability to walk straight 1
Loss of startle behavior 1
Loss of seeking behavior 1
Maximum total 10
Mice are awarded 1 point for each failure to complete a task.
doi:10.1371/journal.pone.0053454.t001
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days 1, 2, and 3. Group 3 received fourteen daily laser Tx (days 1–
14). There were 3 sham-TBI control groups of mice that received
craniotomy but no CCI (group 4 receiving a single anesthesia and
taping, group 5 received 3 daily sessions of anesthesia and taping
and group 6 received 14 daily sessions of anesthesia and taping).
Likewise there were 3 real-TBI sham-treated control groups that
received TBI followed by 1 (group 7), 3 (group 8), and 14 (group 9)
sessions of anesthesia and taping respectively.
2.5 Histomorphology
At the end of the appropriate follow-up period; 4 hours, 4 days,
1 week, 2 weeks, and 4 weeks post TBI, 2 mice per group were
randomly chosen and deeply anesthetized with isoflurane and
subsequently perfused transcardially with 0.9% saline, followed by
4% phosphate-buffered paraformaldehyde. Brains were then
removed from the skull and photographed. All specimens were
fixed in the same formaldehyde solution for 3 days and embedded
in paraffin. 5-mm thick cross-sectional coronal slices were taken
including the injured region of the brain; and 10 micron-thick
sections were cut from the top, middle, and bottom of the thick
slice block by microtome. These 10-micron sections were used for
hematoxylin-eosin (H&E) and Fluoro-Jade staining, while 5
micron-thick coronal sections were taken for BrdU staining. The
brain sections stained with H&E were pictured by using AutoPix
(automated laser capture micro-dissection). The brain lesion
volume was then calculated by multiplying the average lesion
area of the three sections by the thickness of the slices. Fractional
lesion volume is the ratio of difference between non-traumatized
brain volume and hemisphere volume to traumatized lesion
volume.
2.6 BrdU Labeling by Immunohistochemistry
Before sacrifice at 28 days mice (6 per group) were given seven
consecutive daily intraperitoneal injections of 5-bromo-29-deox-
yuridine (BrdU) (Sigma, St Louis, MO) as 50 mg/kg dilution in
saline. Briefly, the unstained paraffin slices were respectively
immersed in xylene for deparaffinization, graded ethanol for
rehydration, and then passed through antigen retrieval with citrate
buffer solution in microwave-oven, incubated in blocking solution
consisting of 5%BSA/0.1%TritonX-100 in PBS, and immuno-
stained with immunostained with the rat anti-BrdU (Abcam,
Cambridge, MA) at 1:50 working concentration. Selected goat
anti-rat secondary antibodies matched with primary antibodies
(Alexa-fluor 594-conjugated, Invitrogen) to stain at a 1:500
concentration. Finally, they were cover-slipped with mounting
media contained DAPI (Fisher Scientific). The BrdU positive cells
were imaged with a confocal microscope (Olympus America Inc,
Center Valley, PA). Red BrdU staining was quantified by the use
of Image J.
2.7 Fluoro-Jade C Staining
The 10 micron-thick slices were first deparaffinized in a slice
warmer, and then respectively immersed in 100% ethanol, a basic
alcohol solution consisting of 1% NaOH in 80% ethanol, followed
by a wash in 70% ethanol. The tissue was briefly rinsed with
distilled water and incubated in 0.06% KMnO4 solution,
afterwards, the slices were transferred to a 0.001% solution of
Fluoro-Jade C (Millipore) dissolved in 0.1% acetic acid. The slices
were rinsed through three changes of distilled water. The air-dried
slices were cleared in xylene and then cover-slipped with DAPI as
above. Green Fluoro-Jade C staining was quantified by the use of
Image J.
2.8 Statistics
Lesion size and labeled cells were measured with Image J
software. Mice numbers were n= 8–16 per group, depending on
how many had been sacrificed. In a two-dimensional coordinate
system, the area-under-the-curve (AUC) data, which represent the
time courses of NSS or WGMT in the various groups of mice,
were calculated using numerical integration [31]. Data are
presented as mean 6 SD, and statistically analyzed using one-
way analysis of variance (ANOVA) followed by Tukey post-hoc
test for multiple comparisons. Significance was defined as p,0.05.
SPSS statistics V17.0 software was used for statistical analyses.
Results
3.1 Neurobehavioral Evaluation
The neurological behavior was evaluated by NSS (Fig. 1A–1C).
The deficits in neurobehavioral function in all groups of mice with
severe TBI gradually but steadily improved as time passed after
the induction of TBI. However, we observed greater improve-
ments in group 1 (single laser Tx given at 4hours post TBI; Fig. 1A)
compared to group 7 (real-TBI, one immobilization and no laser)
that became especially noticeable as time progressed up to 28 days
post-TBI. The improvement seen in group 2 that received three
laser treatments on days 1–3 post-TBI was even more pronounced
and statistically significant (P,0.05) when compared to control
group 8 (real-TBI 3-sham Tx; Fig. 1B). Group 3 that received 14-
daily laser Tx; Fig. 1C) showed improvement in NSS until day 5 at
which point the mice had received 5 daily laser Tx. However, the
improvement then ceased, as more laser Tx were given, and at day
14, the advantage over group 9 (real-TBI 14 sham Tx) had
disappeared. At day 28 there was no difference compared to TBI-
sham Tx group 9. Figure 1D shows the integrated time courses of
the NSS scores. The values for mice with real-TBI and receiving
both 1 laser Tx and 3 laser Tx were significantly better (P,0.001)
then the corresponding real-TBI sham Tx groups. Furthermore
the values for real-TBI 3 active laser Tx was significantly better
(P,0.01) than real-TBI 1 active laser Tx. The integrated NSS
value of the group of real-TBI 14 active laser Tx was significantly
worse than the group of real-TBI 3 active laser Tx (P,0.001) and
also worse that the group of real-TBI 1 active laser Tx (P,0.01).
3.2. Muscular and Vestibulomotor Evaluation
The results for muscle power and motor function were
evaluated by WGMT (Fig. 2A–2C). There were similar overall
findings to those found for the NSS. Group 1 (1 laser Tx; Fig. 2A)
improved compared to real-TBI sham-Tx group 7. Group 2 (3
laser Tx; Fig. 2B) showed a greater improvement over real-TBI 3
sham-Tx group 8, while group 3 (14 laser Tx; Fig. 2C) showed no
Table 2. Wire grip and motion score for TBI mice.
Task score
Unable to grasp wire for 30 sec 0
Gripping wire for 60 sec with 1 or 2 paws 1
Jump up and grasp wire with 2 paws 2
Grasp wire with 4 paws and wrap tail around 3
Crawl along the wire for at least 1 inch 4
Crawl along wire to terminal and dismount 5
Maximum total 5
Mice are assessed the score for the best level they reach.
doi:10.1371/journal.pone.0053454.t002
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improvement over real-TBI sham-Tx group 9 at day 28. Figure 2D
shows the integrated time courses of the WGMT scores. The
values for mice with real-TBI and receiving both 1 laser Tx and 3
laser Tx were significantly better (P,0.05) then the corresponding
real-TBI sham Tx groups. Furthermore the values for real-TBI 3
active laser Tx was significantly better (P,0.05) than real-TBI 1
active laser Tx. The integrated WGMT value of the group of real-
TBI 14 active laser Tx was significantly worse than the group of
real-TBI 3 active laser Tx (P,0.01) and but not different from the
group of real-TBI 1 active laser Tx.
3.3. Size of Brain Lesion by Histomorphometry
Examples of H&E stained brain slices taken from mice in the
various groups are shown in Fig. 3A–P. All groups showed an
expansion of the lesion size in the brain over the course of 4 weeks.
This finding suggested that the lesion is developing (expanding) in
size at the same time as the functional NSS and WGMT results
are improving. The quantitative results of the histomorphometry
measurements of the brain lesion volume from mice sacrificed at 1,
2 and 4 weeks post-TBI are shown in Fig. 3Q. There was no
difference in lesion volume between any of the groups at 7 days
post-TBI. The mean lesion size of group 2 (3 Tx LLLT) or group 1
(1 Tx LLLT) was smaller than other TBI control groups at both 14
and 28 days (P,0.01 or P,0.05), while the result of the 3-time-
LLLT group was better than that of the single laser Tx. The mean
lesion volume of the mice that received 14 laser Tx was not
significantly different from real-TBI sham-Tx control at any time
point. These data are in agreement with the previous neurobe-
havioral evaluations (NSS and WGMT).
3.4. Fluoro-Jade C Staining
Fluoro Jade C staining is used as a specific marker of
degenerating neurons. In this study it was carried out at day 14
in the lesion area. The results from Fluoro-Jade C staining at day
14 showed (Fig. 4) that sham-TBI control mice (Fig. 4A) had
virtually none as expected, there was robust staining in real-TBI
sham Tx control mice (Fig. 4B), much less staining in real-TBI
mice with 1 laser Tx (Fig. 4C), even less in real-TBI mice treated
with 3 laser Tx (Fig. 4D), but noticeably more Fluoro Jade staining
in real-TBI mice treated with 14 laser Tx (Fig. 4E). The mean
Fluoro-Jade staining from 8 slides taken from 2–3 mice per group
is shown in Fig. 4F and the staining in the 3 laser Tx group was
significantly lower (P,0.05) compared to that in the real-TBI
sham Tx group and the real-TBI mice treated with 14 laser Tx.
3.5. BrdU Staining
BrdU staining is used as a marker for proliferating cells as the
compound is injected systemically for several days sacrifice and is
incorporated into the DNA of dividing cells. Its presence can be
readily detected by immunostaining. Effects of different regiments
of LLLT on levels of BrdU at day 28 are shown in Fig. 5. There
were only scattered BrdU+ cells present in sham-control mice,
Figure 1. NSS scores of the mice. Mean (n = 8–14) NSS scores measured over 4 weeks of mice in 9 groups consisting of sham TBI mice, sham
control mice, 810-nm laser treated TBI mice (18 J/cm2 delivered at 25 mW/cm2). (A) Mice and controls given 1 laser Tx or 1 sham Tx at 4 hours post
TBI; (B) Mice and controls given 3 daily laser Tx or 3 sham Tx; (C) Mice and controls given 14 daily laser Tx or 14 sham Tx. * p,0.05; ** P,0.01;
*** p,0.001. One way ANOVA. (D) Mean areas under curve of NSS time courses from mice in different groups. P values given were determined by
one way ANOVA.
doi:10.1371/journal.pone.0053454.g001
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(Fig. 5A) more were seen in TBI-sham untreated mice (Fig. 5B),
and many more in TBI mice that received 1 laser Tx (Fig. 5C).
Mice with 3 laser Tx had even more BrdU+ cells (Fig. 5D) while
there was a sharp drop seen in mice that received 14 laser Tx
(Fig. 5E). The quantification shown in Fig. 5F indicates that the
BrdU staining in the 3-laser Tx group was significantly higher than
real-TBI sham Tx group (P,0.001), real-TBI 1 laser group
(P,0.05) and the real-TBI 14 laser group (P,0.01).
Discussion
This study has shown marked improvement in several
parameters related to neurological, motor and lesion size in mice
subjected to severe CCI-TBI and treated with 1 or 3 (but not 14)
transcranial LLLT treatments. The mechanism appears to involve
both prevention of tissue damage in the short term and increased
brain repair in the longer term due to neurogenesis.
Serious TBI in the acute phase includes skull fracture, acute
cerebral vascular damage, primary mechanical injury to the brain
tissue, and these traumatic events lead to a series of molecular and
cellular reactions that cause secondary brain injury. Once the
brain is damaged, even a very short period of ischemia can cause
significant physiological changes. Mechanical brain injury causes
partial or whole brain blood flow decline, followed by lack of
oxygen and glucose supplies to the neurons. If this situation is
prolonged, it leads to neuronal cell death. Owing to local cerebral
ischemia, cells surrounding the injured region are more sensitive to
pathological changes, and therefore are liable to die in the
succeeding days and weeks after the injury. This area is also known
as the penumbra zone [32].
The brain slices in our study showed that the lesion size or
cavity formation post-TBI underwent a gradual increase in size,
developing from relatively shallow to big and deep, suggesting that
these mice underwent a series of pathological changes of ischemia,
hypoxia, metabolic disorder, edema, necrosis, infarction, collapse,
and tissue absorption. We found that although local lesion sizes
post-TBI become larger gradually over 1 month, contrarily, the
neurobehavioral function and motor function in TBI mice
progressively improved over the same period. This observation
may be possibly explained by the phenomenon of neuroplasticity,
a process whereby distant areas of the brain can adapt to take over
the functions of damaged areas of the brain. In the present case it
is possible that the contralateral cerebral cortex can gradually take
over the functions previously undertaken by the damaged cortex.
The lesion size at both 14 and 28 days in mice treated with 1 or
3 LLLT Tx was significantly smaller than that in TBI control
groups and also less than that seen in mice that received 14 LLLT
Tx. This suggests that the laser is preventing or slowing down the
development of the secondary brain injury.
The results of the performance assays, both NSS and WGMT,
indicated that an optimized LLLT repetition regimen would
produce the optimum effect on neurological, cognitive and motor
Figure 2. WGMT scores of the mice. Mean (n = 8–14) WGMT scores measured over 4 weeks, of mice in 9 groups consisting of sham TBI mice,
sham control mice, 810-nm laser treated TBI mice (18 J/cm2 delivered at 25 mW/cm2). (A) Mice and controls given 1 laser Tx or 1 sham Tx at 4 hours
post TBI; (B) Mice and controls given 3 daily laser Tx or 3 sham Tx; (C) Mice and controls given 14 daily laser Tx or 14 sham Tx. (D) Mean areas under
curve of WGMT time courses from mice in different groups. P values given were determined by one-way ANOVA.
doi:10.1371/journal.pone.0053454.g002
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function post-TBI. In every case 1-laser Tx was effective compared
to the appropriate sham treated control, while the effect of 3-laser
Tx was best, and excessively repeated LLLT (14 laser Tx) had lost
all its beneficial effect. However, interestingly, even though the
effect of 14 laser Tx at 18 J/cm2 was not as good as other laser
groups, it was not significantly different in comparison with TBI
control group, suggesting that our transcranial LLLT approach
was relatively safe. The ineffectiveness of excessively repeated
applications of LLLT was not surprising. There are two reviews
[28,29] that have collected all the examples of the biphasic dose
response effect in LLLT. LLLT regimens that are based on too
high a fluence (J/cm2), too high an irradiance (mW/cm2), or
repeated too often can all have markedly inferior effects to
regimens based on lower doses of LLLT. This biphasic dose
response has been observed in cell culture, in animal studies and in
clinical cases and trials of LLLT alike.
Previous research [33] showed that TBI induces cognitive
deficit. Moreover, TBI-induced cognitive impairment was related
closely with hippocampal regional excitability or neuronal loss.
Fluid percussion TBI in mice results in significant hippocampal-
dependent cognitive impairment, specifically retrograde amnesia.
In a mouse model of pilocarpine-induced status epilepticus,
hippocampal impairment was found to lead cognitive alterations,
increased anxiety-like behavior, decreased depression-like behav-
ior and impaired spatial learning and memory [34].
There have been five previous reports of transcranial LLLT
having beneficial effects in mouse models of TBI. The first by
Oron et al. [24] used a closed head weight drop model and found
a single application of 808 nm transcranial laser improved NSS
and reduced lesion size. A study by Ando et al [23] employed a
CCI model and compared single applications of pulsed wave (PW)
and CW 810 nm transcranial laser. They found that 10 Hz PW
was superior to CW and 100 Hz PW in improving NSS, reducing
both lesion size and depressive symptoms as measured by forced
swim test and tail suspension test. A report by Khuman et al [22]
compared a single application of 810 nm laser delivered transcra-
nially or directly to the contused brain through the craniotomy in
CCI. They found the direct LLLT improved Morris Water Maze
performance and reduced microgliosis. A second study from Oron
et al [21] in their weight drop model compared a single
application of CW and 100 Hz PW 810 nm laser delivered 4, 6,
or 8 hours post-TBI. The PW was best at improving NSS and the
8 h time delay was ineffective. A recent report from Oron et al
[21] compared four different wavelengths (660 nm, 730 nm,
810 nm and 980 nm) of a single exposure to transcranial laser 4 h
post a weight drop TBI. Both the 660 nm and the 810 nm (but not
730 nm or 980 nm) were able to improve the NSS score.
The cellular and molecular mechanisms of LLLT are beginning
to be understood [15]. Red and near-infrared photons are
absorbed in the mitochondria by chromophores such as
cytochrome c oxidase [35]. Increased mitochondrial membrane
potential, increased ATP production [36], modulation of reactive
oxygen species [16], nitric oxide release [37], intracellular calcium
[38] then follow. Signaling pathways and transcription factors are
activated, leading to production of anti-apoptotic, pro-prolifera-
tion, antioxidant, anti-inflammatory and proangiogenic factors
[28]. How these cellular events precisely affect neuroprotection
and neurorepair remains to be elucidated. There have been
numerous studies on transcranial laser therapy (TLT) using
810 nm lasers for stroke [39]. In animal models of stroke, it has
been shown that TLT can improve neurological performance after
occlusion of middle cerebral artery in rats [40] and embolic stroke
in rabbits [41]. The noted success of the animal studies instigated
clinical trials of TLT in human patients [17]. The first study
Figure 3. Brain lesion size in the mice. Example whole brain cross-sections taken from mice sacrificed at day 4 (A–D), day 7 (E–H), day 14 (I–L) and
day 28 (M–P). Mice were taken from TBI sham Tx group (A, E, I, M); TBI 1 laser Tx group (B, F, J, N); TBI 3 laser Tx group (C, G, K, O); TBI 14 laser Tx group
(D, H, L, P). (Q) Mean (n = 2–3) brain fractional lesion volumes calculated as described at 1, 2, and 4 weeks in brains of mice in 4 groups consisting of
sham TBI mice, 810-nm laser treated TBI mice (18 J/cm2 delivered at 25 mW/cm2 given 1, 3 or 14 laser Tx. ** P,0.01; * p,0.05 vs TBI sham and TBI 14
laser Tx groups. One way ANOVA.
doi:10.1371/journal.pone.0053454.g003
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(NEST-1) was successful [42], while the second failed to meet its
primary endpoint [43] but a subsequent sub-analysis found
significant improvement in a sub-set of patients [20]. There has
been one clinical case report [44] of transcranial red/NIR
(633 nm and 870 nm) LED therapy in two chronic TBI patients
giving marked improvement in cognitive function after treatment
once a week for eight weeks.
In the light of accumulated thus far data it was imperative for us
to determine if LLLT could activate brain repair pathways, since
until relatively recently it was thought that the adult brain was
incapable of repairing itself [45]. However since the discovery of
adult neurogenesis, originating in the dentate gyrus of the
hippocampus and in the sub-ventricular zone of the lateral
ventricle, this view has been overturned [46]. It is now thought
that neuroprogenitor cells can be stimulated, especially in response
to brain injuries suffered as a result of stroke or TBI, and that these
cells may be able to migrate to the sites of brain damage to effect
repairs [47]. BrdU is a synthetic thymidine analog that gets
incorporated into cellular DNA when the cell is dividing (during
the S-phase of the cell cycle), therefore, it is commonly used to
detect proliferating cells in living tissues [48]. In our current study
we discovered that the correct regimen of LLLT (1 or 3 daily laser
Tx) could induce abundant BrdU positive cells in the lesion region
at day 28 post-TBI, while the sham treated TBI control group
hardly ever showed BrdU+ cells in the lesion region. It is
important to point out that these cells are capable of generating
new mature neurons in the pericontusional cortex and striatum
[49,50,51], so if our future research can confirm that LLLT can
increase neurogenesis in the damaged brain (or even in the normal
brain), the number of possible applications of transcranial LLLT
will increase dramatically.
The neuropathological study of Schmued, et al. [52] showed
that Fluoro-Jade C, an anionic dye, can stain all degenerating
neurons, regardless of specific insult or mechanism of cell death
with high fidelity and resolution. However Fluoro-Jade C labeling
showed greater morphological detail of degenerating neurons than
its predecessors, Fluoro-Jade or Fluoro-Jade B, and was the most
sensitive of the fluorescent markers for neuronal degeneration, in
terms of producing an image of highest resolution and contrast
[53,54]. The ability to label with increased resolution implies that
Fluoro-Jade C possesses a higher affinity for the endogenous
neurodegeneration molecule(s) than its predecessors Fluoro-Jade
or Fluoro-Jade B. Our research showed that the correct regimen of
LLLT (3 or 1 laser Tx) could reduce the Fluoro-Jade C labeling of
cortical neurons, moreover, there was a significant difference in
comparison with TBI control group or excessive 14X-LLLT.
The study reported here have the following caveats: double
staining for BrdU and the mature neuronal marker NeuN
would have confirmed that the BrdU positive were newly
formed neurons rather than proliferating glial cells or even
delayed neuronal apoptosis [55]. We only carried out BrdU
injection before sacrifice at the 28th day time point. In order to
Figure 4. Fluoro Jade C staining of lesion areas in brain sections. All sections were taken from mice sacrificed at 14 days post-TBI. Green is
FJC and blue is DAPI )control for equal numbers of cell nuclei. (A) Sham-TBI control mouse; (B) real-TBI sham Tx mouse. (C) TBI mouse treated with 1
laser Tx. (C) TBI mouse treated with 3 laser Tx (E) TBI mouse treated with 14 laser Tx (F) Mean green staining calculated with Image J from mice (n = 2–
3) in the groups in panels A–E. # P,0.05 vs TBI sham; * P,0.05 vs 14 laser Tx. One way ANOVA.
doi:10.1371/journal.pone.0053454.g004
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obtain a better overall picture of the time course of the
neurogenesis BrdU should be administered at earlier (and
possible even later) time points.
In conclusion, our initial research indicates that transcranial
laser is a promising treatment for TBI in mice. However, selecting
a proper LLLT regimen has shown to be a key factor for optimal
therapeutic effect. Our data demonstrated 3-time LLLT possessed
a better effect on severe TBI in mice than other regimens and that
14-laser Tx had no benefit at 14 or at 28 days. Moreover, our
results can append to the effects of LLLT for TBI in mice where it
could significantly improve neural function, decrease lesion
volume, augment cell proliferation, and even protect the brain
against neuronal damage to some degree. Further studies will
concentrate on the effects of LLLT on the hippocampus and
subventricular zone regions of the brain in the TBI mice as these
are considered to be the principal source of the neuroprogenitor
cells. Our current study results combined with accumulated thus
far in vivo and clinical study data are providing compelling
evidence that LLLT can be a promising intervention avenue in
treatment of neurological impairments and it is worth pursuing
with in depth clinical trials.
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